Surgery Partners (SGRY) concentration risks

The company's disclosed concentration profile is payor-driven, with the revenue base split between two large payor categories rather than distributed across individual customers. Private insurance payors accounted for approximately 52% of patient service revenue in 2025, a high-share structural exposure reflecting the company's positioning in elective and outpatient surgical procedures that predominantly attract commercially insured patients. This is structural in character — the mix reflects the case types and specialties the surgical facilities pursue rather than a dependency on any single insurance company. Government payors, including Medicare and Medicaid programs, contributed approximately 43% of revenue in 2025, a moderate-share structural exposure. The government payor share is subject to reimbursement rate setting at the federal and state levels, and changes in Medicare ambulatory surgery center payment schedules or Medicaid managed care terms can affect a material portion of revenue without any change in procedure volume. Together the two categories account for virtually all patient service revenue, leaving the business almost entirely exposed to payor policy decisions. The private insurance and government shares move with different drivers — commercial contracting cycles versus regulatory rate-setting — which provides some diversification of mechanism. However, both categories can experience simultaneous pressure during periods of broad healthcare cost containment. On balance, payor reimbursement rates are the dominant variable in the concentration profile, and the government payor share is the dimension most exposed to policy change.

For the engine’s reasoning on SGRY’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.